| Latest Forum Topics / SingMedical |
 Post Reply
|
|
The Next Medical Stock to watch
|
|
|
LarcRytel123
Member |
27-Jun-2018 11:06
|
|
x 0
x 0 Alert Admin |
https://stocknewsnow.com/commentary/ANEWSID16092015100002/AMWS-Rights-Exercised-Price-vs-Stock-Price Further information in this article however I would answer no to your question. |
| Useful To Me Not Useful To Me | |
|
casarasa
Member |
20-Jun-2018 13:01
|
|
x 0
x 0 Alert Admin |
now that the market price is 0.46, just wondering whether will people still exercise the right issue price of 0.48 ? any bro has any view on this? |
| Useful To Me Not Useful To Me | |
|
|
|
|
ysh2006
Supreme |
17-May-2018 15:38
|
|
x 0
x 0 Alert Admin |
When ask my guru why result good share no run ? he said must have BB to play, no BB no play !! |
| Useful To Me Not Useful To Me | |
|
BillionX
Senior |
17-May-2018 14:43
|
|
x 0
x 0 Alert Admin |
A gem in the making.Major shareholders are driving the group and we can only expect positive results.Invest now and enjoy the ride. |
| Useful To Me Not Useful To Me | |
|
beltrance
Senior |
15-Mar-2018 13:16
|
|
x 0
x 0 Alert Admin |
i added at 0.50. long term this should be very good investment. |
| Useful To Me Not Useful To Me | |
|
|
|
|
NickRevell
Member |
07-Mar-2018 06:42
|
|
x 0
x 0 Alert Admin |
Financials look strong. I would get in earlier. Price will start to rise again, once issue completed.. |
| Useful To Me Not Useful To Me | |
|
flyersummer
Senior |
06-Mar-2018 21:54
|
|
x 0
x 0 Alert Admin |
first let me subscribe to the rights. |
| Useful To Me Not Useful To Me | |
|
casarasa
Member |
06-Mar-2018 10:22
|
|
x 0
x 0 Alert Admin |
Price has dropped by about 10% since before its proposed rights announcement. For those who believe in the company' s future, it will be a good time to buy/accummulate. Most broking houses have target price higher than current value. |
| Useful To Me Not Useful To Me | |
|
|
|
|
calvinlooi
Senior |
04-Mar-2018 16:08
|
|
x 1
x 0 Alert Admin |
I think the dropping of price as a result of right issue already partly reflected in the recent drop from 0.60 to 0.55. Those insider already taken the first round of sell down BEFORE the announcement of right issue. |
| Useful To Me Not Useful To Me | |
|
flyersummer
Senior |
04-Mar-2018 15:46
|
|
x 0
x 0 Alert Admin |
Looking past their rights issue, share pricing going down etc.... Ask yourself this questions: . . 1. Is the company doing well? Is the balance sheet good? 2. Does the management has acute business sense (from what they are doing in the past till now, and in the future? 3. Moving forward, can their good performance and aggressive growth propel their share price to $80.00 or beyond may be in the next 2 years? 4. Are you willing to be in the game with the management? 5. Are you able to stomach the paper loss currently since we are forward looking? 6. Are you able to buy in more share if it is reasonably priced/ cheap after the exercise? . . For me: I see this as positive as management also wants us to be aligned with the company direction. Have some skin in the game as well. I also bought above 0.60. I will subscribe to excess rights. i will buy in more shares if the time/ price is right. I will hold. |
| Useful To Me Not Useful To Me | |
|
flyersummer
Senior |
03-Mar-2018 22:40
|
|
x 0
x 0 Alert Admin |
theoretically if all newly issued shares are 100% subscribed at the given price at 0.48. the price traded after XR should be: =(((453000000*0.55)+(23040500*0.48))/(453000000+23040500)) = $0.55 What about those who bought it before XR at may be $0.60/ share? Should he be lowering his cost/ share by subscribing to excess right? (note: may not get the no. of excess you wanted) and there' s no guarantee that price might not go lower than $0.55 before CR. selling the nil-paid rights and buy more shares in the market (after XR) may be a viable options. Irrevocable Undertaking by SMG Directors/ CEO ____________________ The Substantial Shareholders or Directors of the company may give their support for the Rights Issue to demonstrate their commitment and confidence in the prospects of the Company. They will give their irrevocable undertakings to subscribe for the Right Shares which are not fully taken up by other shareholders. With the irrevocable undertakings by the Substantial Shareholders or Directors, the Company may then pursue a Rights Issue on a non-underwritten basis, thereby bringing about cost savings in the form of the underwriting fee. |
| Useful To Me Not Useful To Me | |
|
flyersummer
Senior |
02-Mar-2018 23:41
|
|
x 0
x 0 Alert Admin |
They will send you the docs |
| Useful To Me Not Useful To Me | |
|
|
|
|
animeng
Member |
02-Mar-2018 15:49
|
|
x 0
x 0 Alert Admin |
Any idea when' s the right issue record date? Not released yet? |
| Useful To Me Not Useful To Me | |
|
flyersummer
Senior |
02-Mar-2018 08:19
|
|
x 0
x 0 Alert Admin |
Prepare for price to go lower |
| Useful To Me Not Useful To Me | |
|
calvinlooi
Senior |
02-Mar-2018 08:06
|
|
x 0
x 0 Alert Admin |
Right issue for acquisition. The share pattern will be like Koh Eco? |
| Useful To Me Not Useful To Me | |
|
calvinlooi
Senior |
01-Mar-2018 11:31
|
|
x 0
x 0 Alert Admin |
Right issue? How would market react? |
| Useful To Me Not Useful To Me | |
|
calvinlooi
Senior |
01-Mar-2018 08:38
|
|
x 0
x 0 Alert Admin |
Good result, 100% increase in gross profit, 200% increase in net profit. |
| Useful To Me Not Useful To Me | |
|
casarasa
Member |
23-Feb-2018 08:51
|
|
x 0
x 0 Alert Admin |
anyone knows when will they be announcing their 2017 result? |
| Useful To Me Not Useful To Me | |
|
eagleeyes1989
Master |
01-Feb-2018 08:54
|
|
x 0
x 0 Alert Admin |
http://www.businesstimes.com.sg/companies-markets/singapore-medical-group-takes-stake-in-australian-ivf-specialist big news? |
| Useful To Me Not Useful To Me | |
|
Msport
Elite |
13-Nov-2017 11:44
|
|
x 0
x 0 Alert Admin |
Top Idea of the Day Singapore Medical Group Ltd (SMG SP): BUY (Initiating coverage) Last Traded Price: S$0.60 Price Target: S$0.75 (Upside 25.0%) Robust growth prognosis Initiate coverage with BUY and TP of S$0.75 on the back of continued robust growth post a successful turnaround Project net profit growth of 292%/32% on ramp-up in diagnostics, recent acquisitions, and margin improvements Further re-rating catalysts to come from acquisitions, better operating performance and overseas ventures TP based on 25x FY18F/19F PE |
| Useful To Me Not Useful To Me | |